1INTRODUCTIONLung cancer is the leading cause of cancer‐related death worldwide, and approximately 12–15% of patients with lung cancer were classified as having small‐cell lung cancer (SCLC). Extensive‐disease (ED)‐SCLC accounts for 60–70% of all SCLC cases, and is characterized by rapid progression. The standard therapy for ED‐SCLC is systemic chemotherapy alone, which could improve the symptom in 60–90% of cases, but most of patients die of the disease within 2 years after diagnosis. Combination therapy, including etoposide in combination with cisplatin or carboplatin, has showed benefic effects in ED‐SCLC. Previous study reported that these regimens resulted in an objective tumor response rate of 73%, and median overall survival (OS) of 10 months. Despite many regimens of targeted therapies and newer chemotherapeutic agents have been developed in the past two decades, the survival outcome for ED‐SCLC patients has not been significantly improved.Amrubicin is a synthetic anthracycline that has demonstrated greater antitumor activity than doxorubicin in several human tumor xenografts implanted in nude mice. Moreover, it almost has no heart damage at cumulative doses, and has no chronic cardiotoxic effects in rabbits and dogs that are found in doxorubicin. A phase 2 study of amrubicin as first‐line therapy showed that amrubicin was
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera